Neuropsychology and epilepsy;Neuropsicología y epilepsia

Revista de Neurologia

Volumn 39, Issue 2, 2004, Pages 166-177

  Campos Castello J ^a,b   Campos Soler, S ^a  

^a UNIVERSIDAD ALFONSO X EL SABIO   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Antiepileptic drugs and cognition; Child neuropsychology and epilepsy; Epilepsy and paediatrics; Side effects of AED

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; VALPROIC ACID; VIGABATRIN;

ATTENTION DEFICIT DISORDER; BEHAVIOR; CHILD; COGNITION; COGNITIVE DEFECT; CONFUSION; DEPRESSION; DRUG EFFECT; DRUG MONITORING; EPILEPSY; HUMAN; HYPERACTIVITY; INFORMATION PROCESSING; IRRITABILITY; LANGUAGE DISABILITY; MEMORY DISORDER; NEUROPSYCHOLOGY; ONSET AGE; POLYPHARMACY; RELIABILITY; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SOMNOLENCE;

EID: 4344670067     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3902.2004184     Document Type: Review

References (70)

1. Dodson WE, Kinsbourne M, Hiltbrunner, B. The assessment of cognitive function in epilepsy. New York: Demos Publishing; 1991.
2. Rutter M, Graham P, Yule WA. A neuropsychiatric study in childhood London: SIMP Heinemann Medical; 1970.
3. Ounsted CH, Richard P, Lindsay J. Temporal lobe epilepsy. Oxford: Blackwell Scientific; 1987.
4. Trostle JA, Hauser WA, Sharbrough FW. Psychological and social adjustment to epilepsy in Rochester, Minnesota. Neurology 1989; 39: 633-7.
5. Hermann BP, Seidenberg M, Schoenfeld J, Davies K. Neuropsychological characteristics of mesial temporal epilepsy. Arch Neurol 1997; 54: 369-76.
6. Alphers WCJ, Aldenkamp AP. Computerized neuropsychological assessment in children with epilepsy. Epilepsia 1990; 31 (Suppl 4): 35-40.
7. Blumer DP, Hermann BP. Behavioral and emotional adjustment in epilepsy. Issues in Epilepsy and Quality of Life. Landover, Maryland, USA: Epilepsy Foundation of America; 1993. p. 1-8.
8. Campos-Castëlló J. Integración escolar en el niño epiléptico. Mapfre Medicina 1999; 10 (Supl 2): 60-6.
9. Campos-Castelló J. Calidad de vida: conducta, aprendizaje y aspectos sociolaborales en epilepsia: guía práctíca, Madrid: Acción Médica; 1994. p. 109-20.
10. Ott D, Siddharth P, Gurbani S, Koh S, Tournay A, Shields WD, et al. Behavioral disorders in pediatric epilepsy: unmet psychiatric need. Epilepsia 2003; 44: 591-7.
11. Lennox WG. Brain injury, drugs an environment as causes of mental delay in epilepsy. Am J Psychiatry 1942; 99: 174-80.
12. Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson R. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999; 40: 590-600.
13. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine and tranylcypromine. Arch Gen Psychiatry 1988; 4: 111-9.
14. Faught E, French J, Harden C, Glun B, Khan A, the Postmarketing Antiepileptic Drug Survey Group (PADS). Adverse effects of topiramate: results of a large postmarketing survey. Epilepsia 1997; 38 (Suppl 8): 97-8.
15. Thompson PJ. La memoria en la epilepsia. Influencia de los medicamentos anticonvulsionantes. In: Temas de actualidad sobre la epilepsia. Aspectos psiquiátricos. Malta: Simposio Geigy; 1982. p. 61-75.
16. Gillham RA. Psychomotor and cognitive function in antiepileptic monotherapy. In Chadwick D, ed. Fourth International Symposium on Sodium Valproate and Epilepsy. London: Royal Society of Medicine Services Limited; 1989. p. 247-52.
17. Trimble MR, ed. La epilepsia y el funcionamiento cognitivo. Leeds: EPDATA 1995; p. 1-2.
18. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. Br Med J 1997; 313: 1169-74.
19. Kwan P, Brodie MJ. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 2001; 357: 216-22.
20. Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003; 44 (Suppl 4): 21-9.
21. Corbett J. Fármacos anticonvulsionantes y deterioro cognitivo. In: Temas de actualidad sobre epilepsia. Aspectos psiquiátricos. Malta: Simposio Geigy; 1982. p. 45-59.
22. García de León M, González L, Cañizares GV. Técnicas psico y neurofisiológicas en el estudio de las funciones cognitivas de los epilépticos, II Premio Iberoamericano de Epilepsia. Madrid: Sanofi; 1987. p. 117-58.
23. Herranz JL. Medicamentos antiepilépticos y función cognitiva. An Esp Pediatría 1992; 36 (Supl 49): 207-11.
24. Vermeulen J, Aldenkamp AP. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res 1995; 22: 65-95.
25. Herranz JL, Armijo JA, Arteaga R. Clinical side efects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children. Epilepsia 1988; 29: 794-804.
26. Painter MJ. Phenobarbital: clinical use. In Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, eds. Antiepileptic drugs. 3 ed. New York: Raven Press; 1989; p. 329-40.
27. Leppik IE, Cloyd JC. Primidone: toxicity. In Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, eds. Antiepileptic drugs. 3 ed. New York: Raven Press; 1989. p. 439-45.
28. Reynolds EH. Phenitoin: toxicity. In Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, eds. Antiepileptic drugs. 3 ed. New York: Raven Press; 1989. p. 241-55.
29. Sillampää M. Carbamazepine. Pharmacology and clinical uses. Acta Neurol Scand 1981; 64 (Suppl 88): p.1-202.
30. Zanet BS, Cohen RA. Reversible valproic acid-induced dementia: a case report. Epilepsia 1986; 27: 234-40.
31. Luna D, Dulac O, Pajot N, Beaumont D. Vigabatrin in the treatment of childhood epilepsies: a single-blind placebo-controlled study. Epilepsia 1989; 30: 430-7.
32. Casas-Fernández C. Datos actuales sobre la vigabatrina. Rev Neurol 2000; 30 (Supl 1): 115-20.
33. Sato S. Benzodiazepines: clonazepam. In Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, eds. Antiepileptic drugs. 3 ed. New York: Raven Press; 1989. p. 765-84.
34. Messenheimer JA, Giorgi L, Risser ME. The tolerability of lamotrigine in children. Drug Saf 2000; 22: 303-12.
35. Culy CH, Goa KL. Lamotrigine: a review of its use in childhood epilepsy. Paediatric Drugs 2000; 2: 299-330.
36. Chadwick D. Gabapentin. In Trimble MR, ed. New anticonvulsants. Chichester, UK: Wiley; 1994. p. 75-90.
37. Wolf SM, Shinnar S, Kang H, Ballaban-Gil K, Moshe SL. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 1994; 35 (Suppl 8): 122.
38. McManaman J, Tam DA. Gabapentin for self-injurious behavior in Lesch-Nyhan syndrome. Pediatr Neurol 1999; 20: 381-2.
39. Sachdeo R, Kramer LD, Rosenberg A, Chadwick D, Cooper P, Doelman J. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992; 32: 386-92.
40. Aldenkamp AP, Baker G, Mulder, Chadwick D, Cooper P, Doelman J. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000; 41: 1167-78.
41. Herranz JL. Topiramato, un nuevo antiepiléptico. Rev Neurol 1997; 25: 1221-5.
42. Reyfe RA, Pledger G, Doose D, Lim P, Ward C. Relationship of steady-state plasma topiramate (TPM) concentration to clinical efficacy and tolerability. Epilepsia 1995; 36 (Suppl 3): S152.
43. Lee S, Sziklas V, Andermann F, Farnham S, Risse G, Gustafson M, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 2003; 44: 339-47.
44. Gerber PE, Haminka L, Connolly MD, Farrell K. Factors associated with behavioral and cognitive abnormalities in children receiving topiramate. Pediatr Neurology 2000; 22: 200-3.
45. Leppik IE. Long-term safety of tiagabine HCI. Epilepsia 1995; 36 (Suppl 3): S149.
46. Herranz JL. Tiagabina: aspectos recientes y recomendaciones para su utilización. Rey Neurol 1998; 27: 101-3.
47. Arroyo S. Estudio abierto con tiagabina en epilepsia parcial. Rey Neurol 2000; 31: 728-32.
48. Uldall P, Bulteau C, Pedersen SA, Dulac O, Lyby K. Tiagabine adjunctive therapy in children with refractory epilepsy: a single-blind dose escalating study. Epilepsy Res 2000; 42: 159-68.
49. Gaily E, Granström ML, Liukkonen E. Oxcarbazepine in the treatment of early childhood epilepsy. J Child Neurol 1997; 12: 496-8.
50. Serdaroglu G, Kurul S, Tutuncouglu S, Dirik E, Sarioglu B. Oxcarbazepine in the treatment of childhood epilepsy. Pediatr Neurol 2003; 28: 37-41.
51. Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol 1993; 44: 529-33.
52. Bird JM, Joseph ZA. Levetiracetam in clinical use: a prospective observational study. Seizure 2003; 12: 613-6.
53. Herranz JL, Rufo-Campos M, Arteaga R. Eficacia del levetiracetam en 43 niños y adolescentes con epilepsia. Rev Neurol 2003; 37: 1005-8.
54. Mula M, Trimble MR, Sander JWA. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure 2004; 13: 55-7.
55. Lagae L, Buyse G, Deconinck A, Ceulemans B. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Pediatric Neurol 2003; 7: 123-8.
56. Duncan JS, Shorvon SD, Trimble MR. Effects of removal of phenytoin, carbamazepine, and valproate on cognitive function. Epilepsia 1990; 31: 584-91.
57. Rugland AL. Neuropsychological assessment of cognitive functioning in children with epilepsy. Epilepsia 1990; 31 (Suppl 4): 41-4.
58. Stores G. Efectos de los fármacos antiepilépticos sobre la conducta en los niños. In: Enfoque actual del tratamiento farmacológico de la epilepsia. Copenhaguen: Sociedad Danesa de Epilepsia; 1985. p. 37-49.
59. Mattson RH, Cramer JA. Phenobarbital: toxicity. In Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, eds. Antiepileptic drugs. 3 ed. New York: Raven Press; 1989. p. 341-55.
60. Schmidt D. Benzodiazepines: diacepam. In Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, eds. Antiepileptic drugs. 3 ed. New York: Raven Press; 1989. p. 735-64.
61. Trimble MR. Antiepileptic drugs, cognitive function, and behavior in children: evidence from recent studies. Epilepsia 1990; 31 (Suppl 4): 30-4.
62. Reynolds EH. Mental effects of antiepileptic medication: a review. Epilepsia 1983; 24 (Suppl 2): 585-95.
63. Prats JM, Garaizar C. Alteraciones neuropsicológicas inducidas por fármacos antiepilépticos. Rev Neurol 1994; 22: 124-6.
64. Martín-Plasencia DP, Maestu, F, Garcia de Sola R. Valoración neuropsicológica del paciente epiléptico. In Villarejo F, ed. Tratamiento de la epilepsia. Madrid: Díaz de Santos; 1997. p. 181-94.
65. Martínez-Zuluaga A, Garaizar C, Zuazo E, Zorrilla J, Prats JM. Tratamiento quirúrgico de las crisis epilépticas en pacientes pediátricos. Rev Neurol 1994; 22: 658-61.
66. Diagnosis: clinical neuropsychology, Cognitive function in epilepsy. Epilepsia 2003; 44 (Suppl 6): 29-30.
67. Aldenkamp AP, Dreifuss FE, Renier WO. Epilepsy in children and adolescents. New York: Raven Press; 1995.
68. Dodson WE, Pellock JM. Pediatric epilepsy: diagnosis and treatment. New York: Demos; 1993.
69. Meador KJ. Current discoveries on the cognitive effects of antiepileptic drugs. Pharmacotherapy 2000; 20 (Suppl): 185-90S.
70. Brunbech L, Sabers A. Effects of antiepileptic drugs on cognitive function in individuals wit epilepsy: a comparative review of newer versus older agents. Drugs 2002; 62: 593-604.